Open-Label, Parallel Group, Multiple-dose Study of Ceftobiprole to Evaluate the Plasma Pharmacokinetics in Adults in Intensive Care Units.

Trial Profile

Open-Label, Parallel Group, Multiple-dose Study of Ceftobiprole to Evaluate the Plasma Pharmacokinetics in Adults in Intensive Care Units.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs Ceftobiprole medocaril (Primary)
  • Indications Community-acquired pneumonia; Nosocomial pneumonia; Skin and soft tissue infections
  • Focus Pharmacokinetics
  • Sponsors Basilea Pharmaceutica
  • Most Recent Events

    • 28 Apr 2015 Results presented at the 25th European Congress of Clinical Microbiology and Infectious Diseases.
    • 27 Jul 2012 Company added in the association field and additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 27 Jul 2012 Actual end date Sep 2010 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top